The rising incidence of infections caused by multidrug-resistant (MDR) gram-negative bacteria has become a serious health threat and a major challenge for intensivists. Against a backdrop of high patient mortality and risk factors for infection in intensive care units (ICU), early adequate therapy is of paramount importance. At a recent Pfizer-sponsored symposium, Dr Asok Kurup, Infectious Disease Physician, Singapore presented the implications of MDR gram-negative infections in critically ill patients in Asia, while Dr Kenneth Chan, Respiratory Physician and Intensivist, Singapore highlighted the role of ceftazidime-avibactam (Zavicefta) and shared published real-world data on ceftazidime-avibactam.
At the recent Pfizer webinar “Pneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?”, Dr Petrick Periyasamy, head of the Hospital Canselor Tuanku Muhriz UKM Infectious Diseases Unit, discussed the currently known epidemiology of adult pneumococcal disease (PD),as well as the impact of vaccines on PD prevention in at-risk populations.
At a Pfizer-sponsored webinar held in collaboration with the Malaysian Medical Association, several distinguished speakers shared their insights into the current SARSCOV-2 pandemic, better known as COVID-19. Topics discussed include current and future therapeutic interventions from both local and global perspectives.
Heart failure (HF) is a global public health concern, affecting about 38 million individuals globally.1 Despite significant medical advances, HF remains a chronic and progressive condition that can negatively affect patients’ quality of life (QoL).2,3 In this case study, Dr Abdul Muizz shares his clinical experience in managing a patient with HF and reduced ejection fraction (HFrEF), following the percutaneous coronary intervention, showing how the initiation of sacubitril/valsartan therapy (an angiotensin receptor/neprilysin inhibitor [ARNI]) changed the clinical outcome of this patient.
Janus kinase inhibitors (JAKIs) have emerged as an effective class of therapy for rheumatoid arthritis (RA).1 At the EULAR virtual symposium, a group of specialists discussed recent updates on tofacitinib (Xeljanz®, Pfizer) – the first-in-class JAKI for the treatment of RA.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.